TALEN

TALEN1-ahr1b

ID
ZDB-TALEN-171017-2
Name
TALEN1-ahr1b
Previous Names
None
Target
Target Sequence 1
5' - CGGTTAAACTCTGAG - 3'
Target Sequence 2
5' - GGAAATGGAAGAAGA - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
mu133 ahr1b
mu134 ahr1b
mu135 ahr1b
mu136 ahr1b
mu144 ahr1b
mu145 ahr1b
Expression
Gene expression in Wild Types + TALEN1-ahr1b
No data available
Phenotype
Phenotype resulting from TALEN1-ahr1b
No data available
Phenotype of all Fish created by or utilizing TALEN1-ahr1b
Phenotype Fish Conditions Figures
dorsal longitudinal anastomotic vessel cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. S3 with image from Sugden et al., 2017
trunk vasculature cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. 4 with image from Sugden et al., 2017
lateral dorsal aorta cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. 4 with image from Sugden et al., 2017
posterior cardinal vein cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 control Fig. S3 with image from Sugden et al., 2017
dorsal aorta cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 control Fig. S3 with image from Sugden et al., 2017
posterior cardinal vein cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. S3 with image from Sugden et al., 2017
dorsal longitudinal anastomotic vessel cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 control Fig. S3 with image from Sugden et al., 2017
posterior communicating artery cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. 4 with image from Sugden et al., 2017
eye cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 control Fig. 4 with image from Sugden et al., 2017
trunk vasculature cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 control Fig. 4 with image from Sugden et al., 2017
eye cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. 4 with image from Sugden et al., 2017
basilar artery cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 control Fig. 4 with image from Sugden et al., 2017
intersegmental vessel cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. S3 with image from Sugden et al., 2017
intersegmental vessel cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 control Fig. S3 with image from Sugden et al., 2017
integument cyp1b1 expression amount, ameliorated ahr2hu3335/hu3335; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. 5 with image from Sugden et al., 2017
basal communicating artery cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. 4 with image from Sugden et al., 2017
posterior communicating artery cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 control Fig. 4 with image from Sugden et al., 2017
lateral dorsal aorta cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 control Fig. 4 with image from Sugden et al., 2017
dorsal aorta cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. S3 with image from Sugden et al., 2017
basal communicating artery cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 control Fig. 4 with image from Sugden et al., 2017
basilar artery cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. 4 with image from Sugden et al., 2017
dorsal longitudinal anastomotic vessel cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. S3 with image from Sugden et al., 2017
trunk vasculature cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. 4 with image from Sugden et al., 2017
lateral dorsal aorta cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. 4 with image from Sugden et al., 2017
posterior cardinal vein cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 control Fig. S3 with image from Sugden et al., 2017
dorsal longitudinal anastomotic vessel cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 control Fig. S3 with image from Sugden et al., 2017
posterior communicating artery cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. 4 with image from Sugden et al., 2017
posterior cardinal vein cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. S3 with image from Sugden et al., 2017
eye cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 control Fig. 4 with image from Sugden et al., 2017
dorsal aorta cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 control Fig. S3 with image from Sugden et al., 2017
central artery cxcr4a expression amount, ameliorated ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. 6 with image from Sugden et al., 2017
trunk vasculature cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 control Fig. 4 with image from Sugden et al., 2017
eye cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. 4 with image from Sugden et al., 2017
intestine vasculature cxcr4a expression amount, ameliorated ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. 6 with image from Sugden et al., 2017
basilar artery cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 control Fig. 4 with image from Sugden et al., 2017
intersegmental vessel cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 control Fig. S3 with image from Sugden et al., 2017
intersegmental vessel cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. S3 with image from Sugden et al., 2017
dorsal longitudinal anastomotic vessel cxcr4a expression increased amount, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 chemical treatment by environment: nifedipine Fig. 6 with image from Sugden et al., 2017
intestine vasculature cxcr4a expression increased amount, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 chemical treatment by environment: nifedipine Fig. 6 with image from Sugden et al., 2017
integument cyp1b1 expression amount, ameliorated ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. 5 with image from Sugden et al., 2017
central artery cxcr4a expression increased amount, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 chemical treatment by environment: nifedipine Fig. 6 with image from Sugden et al., 2017
dorsal aorta cxcr4a expression increased amount, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 chemical treatment by environment: nifedipine Fig. 6 with image from Sugden et al., 2017
basal communicating artery cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. 4 with image from Sugden et al., 2017
lateral dorsal aorta cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 control Fig. 4 with image from Sugden et al., 2017
posterior communicating artery cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 control Fig. 4 with image from Sugden et al., 2017
dorsal aorta cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. S3 with image from Sugden et al., 2017
trunk vasculature cxcr4a expression increased amount, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 chemical treatment by environment: nifedipine Fig. 6 with image from Sugden et al., 2017
basilar artery cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 chemical treatment by environment: beta-naphthoflavone Fig. 4 with image from Sugden et al., 2017
basal communicating artery cyp1a expression absent, abnormal ahr2hu3335/hu3335; ahr1amu153/mu153; ahr1bmu145/mu145 control Fig. 4 with image from Sugden et al., 2017
Citations